ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
12/18/201408:51:07Merck Acquires OncoEthix for Up to $375 Million
12/09/201416:08:36Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling...
12/09/201415:54:02MARKET SNAPSHOT: The S&P 500 Recorded Its Biggest Drop In Nearly...
12/09/201415:50:44Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling
12/08/201422:16:42Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
12/08/201419:12:00Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
12/08/201419:11:47Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update
12/08/201419:04:54MARKET SNAPSHOT: Energy Companies Drag U.S. Stocks Lower
12/08/201418:56:04Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 3rd Update
12/08/201418:54:55U.S. Stocks Down
12/08/201418:51:53Correction to U.S. Stocks Story
12/08/201418:51:25U.S. Stocks Edge Lower
12/08/201418:49:08Correction to Merck-Cubist Deal Story
12/08/201418:02:18MARKET SNAPSHOT: U.S. Stocks: Futures Fall As Global Growth Concerns...
12/08/201412:39:54MARKET SNAPSHOT: U.S. Stocks: Futures Falling, With Dow Poised...
11/24/201409:57:19Bristol-Myers, Five Prime to Collaborate on Immunotherapy
11/17/201411:41:20U.S. Stocks Bounce Back from Early Loses
11/17/201405:11:44Pfizer, Germany's Merck to Develop Tumor Treatment -- Update
10/27/201416:37:41MARKET SNAPSHOT: Energy Stocks Sap S&P 500
10/27/201414:06:16MARKET SNAPSHOT: U.S. Stocks Retreat; Energy Stocks Sell Off

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad